Compile Data Set for Download or QSAR
Report error Found 45 Enz. Inhib. hit(s) with all data for entry = 9720
TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483889(US10927106, Compound 4-93)
Affinity DataIC50: 40nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483905(US10927106, Compound PST-170)
Affinity DataIC50: 43.7nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483913(US10927106, Compound PST-155)
Affinity DataIC50: 51.8nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483894(US10927106, Compound 5-85)
Affinity DataIC50: 56nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483897(US10927106, Compound 1-31)
Affinity DataIC50: 65nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483926(US10927106, Compound PST-098)
Affinity DataIC50: 77.4nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483912(US10927106, Compound PST-156)
Affinity DataIC50: 93.8nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483895(US10927106, Compound 5-51)
Affinity DataIC50: 145nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483911(US10927106, Compound PST-157)
Affinity DataIC50: 150nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483896(US10927106, Compound 1-19)
Affinity DataIC50: 153nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483900(US10927106, Compound 1-17)
Affinity DataIC50: 162nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483916(US10927106, Compound PST-148)
Affinity DataIC50: 171nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483909(US10927106, Compound PST-162)
Affinity DataIC50: 175nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483902(US10927106, Compound PST-206)
Affinity DataIC50: 207nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483899(US10927106, Compound 1-27)
Affinity DataIC50: 208nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483929(US10927106, Compound PST-095)
Affinity DataIC50: 236nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483930(US10927106, Compound PST-087)
Affinity DataIC50: 247nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483890(US10927106, Compound 4-95)
Affinity DataIC50: 260nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483928(US10927106, Compound PST-096)
Affinity DataIC50: 273nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483891(US10927106, Compound 4-99)
Affinity DataIC50: 280nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483906(US10927106, Compound PST-169)
Affinity DataIC50: 281nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483933(US10927106, Compound PST-075)
Affinity DataIC50: 306nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483904(US10927106, Compound PST-173)
Affinity DataIC50: 330nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483931(US10927106, Compound PST-077)
Affinity DataIC50: 337nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483914(US10927106, Compound PST-154)
Affinity DataIC50: 350nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483920(US10927106, Compound PST-129 | US10927106, Compoun...)
Affinity DataIC50: 351nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483898(US10927106, Compound 1-29)
Affinity DataIC50: 375nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483923(US10927106, Compound PST-122)
Affinity DataIC50: 413nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483917(US10927106, Compound PST-147)
Affinity DataIC50: 487nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483927(US10927106, Compound PST-097)
Affinity DataIC50: 488nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483901(US10927106, Compound PST-288)
Affinity DataIC50: 491nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483924(US10927106, Compound PST-120)
Affinity DataIC50: 534nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483907(US10927106, Compound PST-164)
Affinity DataIC50: 593nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483918(US10927106, Compound PST-141)
Affinity DataIC50: 637nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483903(US10927106, Compound PST-201)
Affinity DataIC50: 644nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483915(US10927106, Compound PST-151)
Affinity DataIC50: 644nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483925(US10927106, Compound PST-110)
Affinity DataIC50: 658nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483919(US10927106, Compound PST-134)
Affinity DataIC50: 789nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483922(US10927106, Compound PST-128)
Affinity DataIC50: 808nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483932(US10927106, Compound PST-076)
Affinity DataIC50: 904nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483910(US10927106, Compound PST-158)
Affinity DataIC50: 922nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483893(US10927106, Compound 5-23)
Affinity DataIC50: 3.68E+3nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483920(US10927106, Compound PST-129 | US10927106, Compoun...)
Affinity DataIC50: 3.86E+3nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483908(US10927106, Compound PST-163)
Affinity DataIC50: 5.42E+3nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent

TargetDual specificity tyrosine-phosphorylation-regulated kinase 1A(Human)
Pharmasum Therapeutics

US Patent
LigandPNGBDBM483892(US10927106, Compound 5-25)
Affinity DataIC50: 5.64E+3nMAssay Description:The principal method utilized is a radioactive filter binding assay using 33P ATP This method is sensitive, accurate and provides a direct measure of...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/6/2021
Entry Details
US Patent